Teodora Kaltcheva

City Of Hope National Medical Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index1.0kcitations97works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(34), Tryptophan and brain disorders(32), Cancer Immunotherapy and Biomarkers(21), Gut microbiota and health(19), Immunotherapy and Immune Responses(14)

Publications97 total

Humoral and functional <scp>SARS</scp> ‐ <scp>CoV</scp> ‐2‐specific T‐cell responses elicited in chronic lymphocytic leukaemia patients with <scp>GEO</scp> ‐ <scp>CM04S1</scp> a synthetic <scp>MVA</scp> ‐vectored <scp>COVID</scp> ‐19 vaccine
British Journal of Haematology·2025Open Access
Immunogenicity of Synthetic MVA-based Vaccine COH04S1 Against SARS-CoV-2 in Post-HCT/CAR-T Patients and Its Cross-Protective Potential Against Mpox 9352
The Journal of Immunology·2025Open Access
Abstract A004: Neoantigen Vaccine for Neoadjuvant Therapy of Pancreatic Cancer
Cancer Immunology Research·2025
Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform
npj Vaccines·2024· 4 citedOpen Access
Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on viremia requiring antivirals
Haematologica·2024· 2 citedOpen Access
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplant
Haematologica·2024· 5 citedOpen Access
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy
Vaccines·2023· 4 citedOpen Access
Supplementary Fig. S4 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Supplementary Fig. S12 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Supplementary Fig. S10 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Supplementary Fig. S15 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Supplementary Fig. S10 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Supplementary Fig. S11 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Supplementary Fig. S4 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Data from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Supplementary Fig. S1 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Supplementary Fig. S11 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Supplementary Fig. S13 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Supplementary Fig. S7 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
Supplementary Fig. S14 from &lt;i&gt;Salmonella&lt;/i&gt;-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Coupled with Enzymatic Depletion of Tumor Hyaluronan Induces Complete Regression of Aggressive Pancreatic Tumors
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Don J. Diamond(49), Corinna La Rosa(19), Qiao Zhou(18), Edwin R. Manuel(17), Flavia Chiuppesi(15), Vincent Chung(15), Ryotaro Nakamura(14), Joshua D.I. Ellenhorn(13), Felix Wussow(12), Nicola Hardwick(11), Joy Martinez(9), Yoonsuh Park(9), Ibrahim Aldoss(9), Stephen J. Forman(9), Weimin Tsai(8), Lucille Leong(8), Vu H. Nguyen(7), Mindy Kha(7), Angelina Iniguez(7), Jeff Longmate(7)